How to analyse pharma stocks
Indian pharma companies sell medicines in India and abroad. Many make generics, which are cheaper copies of drugs whose patents have expired, and sell them in the US and other markets. Profit depends on getting approvals, keeping factories compliant with regulators, and managing price falls in crowded markets.
The numbers that matter
| Metric | What it tells you | What healthy looks like |
|---|---|---|
| Revenue mix | How sales split between India, the US and other markets, and between generics and branded products. | A balanced mix, so trouble in one market does not sink the whole company. |
| R&D spend to sales | Money spent on research and developing new products, as a share of sales. | Steady investment that leads to a visible pipeline of new launches. |
| Product filings and approvals | Applications filed with regulators like the USFDA to sell new generics, and how many are approved. | A healthy pipeline of pending approvals and a steady flow of launches. |
| Regulatory status of plants | The inspection record of the company’s factories with the USFDA and other regulators. | Clean inspections, or observations that are closed quickly. |
| Domestic sales growth | Growth in the Indian business, usually built on brands sold through doctors. | Growth at or above the Indian market, led by volume and new launches. |
| Operating margin | Profit after running costs, including R&D, as a share of sales. | Stable over years; a jump from one exclusive product may not last. |
The US generics business
When a drug loses patent protection in the US, many companies launch copies. The first few to launch earn good margins. As more players enter, prices fall sharply. This is called price erosion, and it means a product that earns well in its first year may earn much less later.
Sometimes a company gets a limited-period exclusive right to sell a generic. Profits can jump during that period and then drop when it ends. Do not treat that jump as the new normal.
Why USFDA inspections matter
The USFDA inspects factories that make drugs for the US market. If inspectors find problems, they issue observations, often called a Form 483. Serious or unresolved problems can lead to a warning letter or an import alert, which can block products from that plant reaching the US.
A blocked plant can stall new approvals for years. Always check the status of key plants before judging growth plans.
The Indian market
The domestic business sells branded generics through doctors and chemists. It is usually steadier than exports. Some essential medicines are under government price control, which limits how much those prices can rise.
Red flags
- A warning letter or import alert on a plant that makes a large share of US sales.
- Profit growth driven by one exclusive product with a fixed end date.
- R&D spending cut sharply to protect margins.
- Repeated inspection observations at the same plant.
- Receivable days rising, especially in export markets.
Common beginner mistakes
- Treating a one-time exclusive product windfall as lasting growth.
- Ignoring the inspection history of the company’s key plants.
- Comparing a domestic-focused pharma company directly with a US-focused one.
- Judging R&D spending only as a cost instead of as future products.
Common questions
What does a USFDA warning letter mean for a pharma stock?
It means the regulator found serious problems at a plant. New approvals from that plant can be held back until the issues are fixed, which can slow US growth.
What is price erosion in pharma?
It is the steady fall in prices of a generic drug as more companies start selling it. It means early profits on a product usually shrink over time.
How do I analyse a pharma company’s growth?
Look at its revenue mix, pipeline of filings and approvals, R&D spending, plant inspection record and domestic sales growth together.
Practise reading company numbers, free
Short chapters, then real calls graded on your reasoning, not luck. No money involved.